Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
AML|ALL|MDS|MPD Withou Myelofibrosis|NHL or HL|Inherited Metabolic Disorders|Hemoglobinopathies|Bone Marrow Failure|HLH
DRUG: Clofarabine|DRUG: Fludarabine|DRUG: Busulfan|DRUG: Cyclosporine-A|DRUG: Mycophenolate Mofetil|BIOLOGICAL: Cord Blood Graft
Treatment related mortality at 1 year after myeloablative cord transplant, The primary objective of this study is to assess treatment related mortality (TRM) at 1 year after myeloablative cord transplant., 1 year
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.